[go: up one dir, main page]

EP0000220B1 - Dihydrouraciles, procédé pour leur préparation et médicaments les contenant - Google Patents

Dihydrouraciles, procédé pour leur préparation et médicaments les contenant Download PDF

Info

Publication number
EP0000220B1
EP0000220B1 EP78200041A EP78200041A EP0000220B1 EP 0000220 B1 EP0000220 B1 EP 0000220B1 EP 78200041 A EP78200041 A EP 78200041A EP 78200041 A EP78200041 A EP 78200041A EP 0000220 B1 EP0000220 B1 EP 0000220B1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
group
phenyl
dihydrouracil
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78200041A
Other languages
German (de)
English (en)
Other versions
EP0000220A1 (fr
Inventor
Rolf-Ortwin Dr. Weber
Hiristo Anagnostopulos
Ulrich Dr. Gebert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of EP0000220A1 publication Critical patent/EP0000220A1/fr
Application granted granted Critical
Publication of EP0000220B1 publication Critical patent/EP0000220B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • the present invention relates to dihydrouracils including their salts, processes for their preparation and medicaments which contain these compounds as active ingredients.
  • Piperazine compounds are already known from German laid-open specification 2,242,382 which, in addition to a trifluoromethylphenyl group, can also carry a dihydrouracil radical. However, nothing is reported about their pharmacological effects.
  • the analog succinimide compounds described there only have appetite-inhibiting properties. It was therefore not foreseeable that derivatives of such dihydrouracils which do not carry a trifluoromethyl group on the phenyl ring and which have alkyl substituents on the dihydrouracil ring show completely different pharmacological effects.
  • the invention thus relates to compounds of the formula (I), including their addition salts, with physiologically tolerated acids.
  • the compounds according to the invention exhibit antihistaminic activity, an increase in erythrocyte fluidity, in some cases also psychotropic activity, a weak bradykinin antagonism and hypotensive effects.
  • R ' is methyl
  • one of the radicals R 2 and R 3 is methyl and the other is hydrogen
  • R 6 is hydrogen or fluorine in the 4-position, such as compounds Nos. 8, 10 and 14 to 16 of the Table IV.
  • Suitable groupings are, for example, phenyl, 2-, 3- or 4-tolyl, 2,6- or 3,4-dimethylphenyl, 2-, 3- or 4-methoxyphenyl, naphthyl, fluorophenyl, chlorophenyl, bromophenyl or diphenylmethyl.
  • Suitable groupings are, for example, 5,6- or 6,6-dimethyl-dihydrouracil-3-yl; 5,6- or 6,6-dimethyl-2-thio-dihydrouracil-3-yl; 1,6,6-trimethyl-2-thio-dihydrouracil-3-yl; 1,6,6-trimethyl-dihydrouracil-3-yl; 6-methyl-dihydrouracil-3-yl.
  • Suitable bridge members Q are, for example, ethylene, propylene, butylene, pentylene, hexylene and 2-hydroxypropylene, it being possible for the radicals with at least 3 C atoms to be branched off, so that at least 2 C atoms are still in the chain.
  • the invention also relates to a process for the preparation of dihydrouracils of the formula (1), in which a compound of the formula II in which R 1 to R 6 , A, Q, Z and X have the meanings given above and OR 7 is hydroxyl or an alkoxy group having 1 to 4 carbon atoms, cyclized with elimination of R 7 0H and, if desired, the compounds of the formula I. isolated as such or converted with acids into their physiologically acceptable acid addition salts.
  • the cyclization of the compound II can be carried out in various ways by conventional condensation methods, especially in a suitable solvent and / or in the presence of mineral acids and / or by heating the reaction mixture obtained in the synthesis of the compound II or the pure substance II isolated therefrom.
  • Compounds in which R 7 represents hydrogen can often be cyclized particularly well with the aid of mineral acids, such as sulfuric acid or hydrohalic acids, preferably hydrochloric acid or hydrobromic acid, in an alcohol such as methanol, ethanol, propanol or isopropanol.
  • the cyclization can, which is preferred, be achieved by heating the pure substances with elimination of water or without addition of solvent and acid by means of suitable dehydrating agents, such as acetyl chloride or acetic anhydride. It is advisable to work at the boiling point of the corresponding solvent or condensing agent.
  • the cyclization of compounds in which R 7 is alkyl is preferably carried out in a suitable solvent and / or in the presence of mineral acids, for example the abovementioned acids and alcohols.
  • mineral acids for example the abovementioned acids and alcohols.
  • X sulfur
  • cyclization in solvents without the addition of mineral acids is particularly preferred.
  • compounds of the formula II in which R 7 is alkyl having 1 to 4 carbon atoms first hydrolyzing with an alkali metal hydroxide to give a compound of the formula II in which R 7 is hydrogen, and then cyclizing it.
  • This hydrolysis can advantageously be carried out in aqueous or aqueous-acetone or aqueous-alcoholic medium, the alcohol advantageously having 1 to 3 carbon atoms.
  • Suitable starting materials of the formula (III) are, for example, 1-phenyl-4- (3-aminopropyl) piperazine, 1- (2-methylphenyl) and 1- (3-methylphenyl) -4- (3-aminopropyl) piperazine, 1- (2-methoxyphenyl) -1- (3-methoxyphenyl) - and 1- (4-methoxyphenyl) -4- (3-aminopropyl) piperazine, 1- (3-dimethylphenyl) - and 1- (2.6 -Dimethylphenyl) -4- (3-aminopropyl) piperazine, 1- (1-naphthyl) - and 1- (4-fluorine phenyl) -4- (3-aminopropyl) piperazine, 1-phenyl-4- (2-aminoethyl) piperazine, 1- (2-methoxyphenyl) -4- (2-aminoethyl) piperazine, 1- (4- Methoxyphen
  • Suitable 3-isocyanato- or isothiocyanatoalkanecarboxylic acid esters of the formula (IV) are, for example, 3-isocyanato-isovaleric acid methyl ester and ethyl ester, 3-isocyanato-isovaleric acid n-and isopropyl ester, the various 3-isocyanato-isovaleric acid butyl ester, 3-isocyanato-isoisoisalerate ester, and isopropyl ester, the various 3-isothiocyanatoisovalerianklabutylester, 2-methyl-3-isocyanatobutterklad- and 2-methyl-3-isothiocyanatobutterklaklad.
  • Suitable 3-aminoalkanecarboxylic acid derivatives of the formula (VII) are, for example, those which correspond to the isocyanato compounds mentioned above and which contain an amino group in the 3-position instead of the isocyanato group, such as 3-aminoisovaleric acid methyl ester, 3-amino-2-methylbutyric acid methyl ester and 3 -Methylaminoisovalerianklaremethylester.
  • the reactants such as xylene, toluene, mesitylene, benzene, methylene chloride or chloro
  • Process variants b) and c) can generally be carried out at room temperature and expediently as a one-pot process.
  • process (b) which proceeds particularly well in tetrahydrofuran, the further reaction and the cyclization described above are advantageously carried out at the boiling point of the reaction mixture after addition of compound VII.
  • Compounds of formula II; in which R 7 is hydrogen are preferably - after they are isolated in pure form - cyclized by heating without solvent; and advantageously at temperatures above 150 ° C, preferably at about 200 ° C and under protective gas.
  • Physiologically compatible mineral or sulfonic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid and cyclohexylsulfamic acid, are suitable for the preparation of the mono- or bisaddition salts, which is carried out by the generally customary methods.
  • the stability of the compounds obtained according to the invention allows the preparation of pharmaceutical preparations for oral, parenteral and rectal administration.
  • the preparation of these preparations can be made according to the usual practice by admixing suitable and compatible auxiliaries, such as starch, milk sugar, cellulose derivatives, stearic acid or its salts, solvents, solubilizers, suppository mass, carriers such as chlorides, phosphates and carbonates in the usual way to form powders, tablets, dragees , Capsules, suppositories, solutions, pastes or suspensions. It is also possible to administer the pure substances in the form of microcapsules and also to combine them with other active substances.
  • Your dosage in humans is 0.1 to 50 mg, preferably 0.5 to 10 mg, in particular 0.5 to 3 mg per os per day.
  • the assessment is made 1 hour after administration of the preparation by measuring the amount of faeces excreted. A reduction of this amount by ⁇ 25% of the empty check is given depending on the result with 0 or (+), from 25 to 50% with +, from 50 to 75% with ++ and > 75% with +++ (see table I).
  • mice and rats in intraperitoneal and intravenous administration via mortality occurring within 7 days as the LD 50 and LD 50 range are given in Table III.
  • the compounds obtained according to the invention are largely superior to the comparative preparation Pizotifen-HCl.
  • animal experiments have shown further advantages over Pizotifen-HCI in such a way that a) the effect occurs much faster, b) no sedation is caused in the therapeutic dose range and c) no unwanted appetite stimulation is caused.
  • a particular application of the compounds of formula (1) and their salts obtained according to the invention is in the combination with other suitable active ingredients, such as analgesics, ergotamine preparations, other serotonin antagonists, spasmolytics, vasodilatants, ⁇ -sympatholytics, antemetics, antihistamines, sedatives, tranquillizers , Caffeine, nicotinic acid derivatives, vitamins and estrogens.
  • suitable active ingredients such as analgesics, ergotamine preparations, other serotonin antagonists, spasmolytics, vasodilatants, ⁇ -sympatholytics, antemetics, antihistamines, sedatives, tranquillizers , Caffeine, nicotinic acid derivatives, vitamins and estrogens.
  • the base is dissolved in acetone and the equimolar amount of 1N hydrochloric acid is added.
  • the solvent is removed under reduced pressure at a maximum of 30 ° C. and the residue is recrystallized from dioxane, whereby the intermediate 3 - [3 - (3 - ⁇ 4 - phenyl - piperazino) - propyl) - ureidoJ - isovaleric acid methyl ester - hydrochloride in pure Takes shape. Yield quantitative; Melting range 168 to 170 ° C; C 20 H 33 CIN 4 0 3 ; Molecular weight 412.96.
  • the compound is dissolved in about 10 times the amount of 12% hydrochloric acid and boiled under reflux for two hours, about half of the solvent being distilled off under normal pressure within the last hour. It is evaporated under reduced pressure, the residue is dissolved in water and an excess of aqueous sodium hydroxide solution is added. The precipitated base is taken up in methylene chloride, dried over sodium sulfate and, after evaporation, recrystallized from a mixture of methanol and diisopropyl ether. Melting range 135 to 136 ° C.
  • the cyclization can also be carried out by mixing 5.65 g (0.015 mol) of 3- [3- (3- ⁇ 4-phenyt-piperazino) propyl) ureido] isovaleric acid methyl ester under a nitrogen atmosphere at 200 ° C. for 1.5 hours heated. The course of the cyclization is followed by thin layer chromatography. After the reaction has ended, the solidified melt is rubbed with diisopropyl ether, purified on a chromatography column and recrystallized from methanol-diisopropyl ether. Yield: 2.5 g (48% of theory); Melting range: 134 to 136 ° C.
  • the base is dissolved in methanol and the calculated amount of 1N hydrochloric acid is added. After evaporation under reduced pressure, the residue is recrystallized from methanol or water. Melting range 236 to 242 ° C; Molecular formula C 19 H 29 CIN 4 0 2 ; Molecular weight: 380.92.
  • a solution of 21.9 g (0.1 mol) of 1-phenyl-4- (3-aminopropyl) piperazine in 100 ml of toluene is, according to procedure a), with stirring, with a mixture of 15.7 g (0.1 mol ) 3-Isocyanatoisovalerianklaremethylester and 100 ml of toluene.
  • the mixture is briefly heated to boiling, cooled to room temperature, evaporated to dryness and the residue is dissolved in about 1 liter of acetone. After adding 100 ml (0.1 mol) of 1N sodium hydroxide solution, the reaction mixture is stirred for 20 hours at room temperature.
  • the intermediate product thus obtained is heated to 180-200 ° C for 1 hour. After cooling, the solidified base is purified by column chromatography and recrystallized from a mixture of methanol and diisopropyl ether. Melting range: 135 to 136 ° C.
  • the cyclization of the open-chain carboxylic acid to the corresponding 5,6-dihydrouracil can be carried out by heating in aqueous-alcoholic hydrochloric acid, acetyl chloride or acetic anhydride for two hours. After removing the corresponding condensing agent (dehydrating agent) under reduced pressure, the residue is dissolved in water and excess potassium hydroxide solution is added. The precipitated base is taken up in methylene chloride, dried over sodium sulfate and, if necessary, purified by column chromatography after evaporating the extractant.
  • the compound can then be converted into the salts desired in each case by the customary methods.
  • a solution of 25.8 g (0.145 mol) of N, N'-thiocarbonyldi-imidazole in 500 ml of anhydrous tetrahydrofuran is 29.8 g (0.145 mol) of 1-phenyl-4- (2-aminoethyl) piperazine drop in 125 ml of anhydrous tetrahydrofuran within 90 minutes with stirring added wisely.
  • the mixture is stirred for 90 minutes and then 24.3 g (0.145) mol) of anhydrous 3-aminoisovaieric acid methyl) ester hydrochloride are also added with stirring.
  • the clear solution is refluxed for 120 minutes.
  • the base is dissolved in methylene chloride and an excess of ethanolic hydrochloric acid is added. After adding diethyl ether, a colorless crystalline substance is obtained, which is recrystallized twice from ethanol and which is monohydrochloride.
  • the pH of a 0.1% aqueous solution is 4.3. Melting range 239 to 240 ° C; Molecular formula: C 18 H 27 CIN 4 OS; Molecular weight 382.95.
  • the base is dissolved in a little water-containing methanol and an excess of alcoholic hydrochloric acid is added. After precipitation with diethyl ether, the desired compound is obtained, which is freed from adhering hydrochloric acid under reduced pressure at room temperature and dried over calcium chloride.
  • the pH of a 10% aqueous solution is 1.8. Melting range 238 to 247 ° C with decomposition; Molecular formula C 18 H 30 CI 2 N 4 O 2 S; Molecular weight 437.42.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (10)

1. Dihydrouraciles de formule 1
Figure imgb0046
dans laquelle:
R1 représente un radical alkyle ayant jusqu'à 2 atomes de carbone,
R2 à R5 représentent l'hydrogène ou un alkyle radical ayant jusqu'à 2 atomes de carbone, R2 à R5 étant identiques ou différents,
R6 représente l'hydrogène, un noyau benzènique condensé ou de 1 à 3 substituants choisis parmi les radicaux alcoxy ayant de 1 à 3 atomes de carbone, les halogènes et les radicaux alkyle ayant jusqu'à 4 atomes de carbone;
A représente une simple liaison ou le groupe
Figure imgb0047
Q représente un radical alkylène ayant de 2 à 6 atomes de carbone, avec au moins 2 atomes de carbone intercalés entre les deux atomes d'azote, ou le groupe 2-hydroxy-1,3-propylène,
X représente l'oxygène ou le soufre, et
Z représente l'azote ou le groupe
Figure imgb0048
et leurs sels d'addition avec des acides physiologiquement acceptables.
2. Composés selon la revendication 1, caractérisés en ce que:
RI représente un radical alkyle ayant jusqu'à 2 atomes de carbone,
R2, R3 représentent l'hydrogène ou un radical alkyle ayant jusqu'à 2 atomes de carbone,
R4, R5 représentent l'hydrogène,
R6 représente l'hydrogène ou un halogène
A représente une simple liaison
Q représente une chaîne alkylène non-ramifiée ayant de 2 à 3 atomes de carbone,
X représente l'oxygène ou le soufre, et
Z représente l'azote.
3. Composé selon la revendication 2, caractérisé en ce que R1 représente un groupe méthyle, un des radicaux R2 et R3 représente un groupe méthyle et l'autre l'hydrogène et R6 représente l'hydrogène ou le fluor en position 4.
4. Chlorhydrate hydraté de 3 - [3 - (4 - (4 - fluorphényl) - 1 - pipérazinyl) - propyl] - 6,6 - diméthyl - dihydrouracile, selon la revendication 1.
5. Chlorhydrate de 3 - [3 - (4 - phényl - 1 - pipérazinyl) - propyl] - 6,6 - diméthyl - dihydrouracile, selon la revendication 1.
6. Chlorhydrate de 3 - [3 - (4 - phényl - pipérazinyl) - propyl] - 6,6 - diméthyl - 2 - thio - dihydrouracile, selon la revendication 1.
7. Chlorhydrate de 3 - [3 - (4 - phényl - pipérazinyl) - propyl] - 5,6 - diméthyl - dihydrouracile, selon la revendication 1.
8. Chlorhydrate de 3 - [2 - (4 - phényl - 1 - pipérazinyl) - éthyl] - 6,6 - diméthyl - 2 - thio - dihydrouracile, selon la revendication 1.
9. Procédé de préparation des dihydrouraciles selon la revendication 1, caractérisé en ce qu'on cyclise un composé de formule Il
Figure imgb0049
dans laquelle R1 à R6, A, Q, Z et X ont les significations indiquées dans la revendication 1, et OR7 représente un hydroxyle ou un radical alcoxy ayant de 1 à 4 atomes de carbone, avec séparation de R70H, et éventuellement on isole les composés de formule 1 tels que ou on les convertit avec des acides en leurs sels d'addition avec des acides physiologiquement acceptables.
10. Médicament, caractérisé en ce qu'il contient au moins un composé selon la revendication 1, seul ou associé à des additifs usuels.
EP78200041A 1977-06-18 1978-06-14 Dihydrouraciles, procédé pour leur préparation et médicaments les contenant Expired EP0000220B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772727469 DE2727469A1 (de) 1977-06-18 1977-06-18 Neue hexahydropyrimidine, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
DE2727469 1977-06-18

Publications (2)

Publication Number Publication Date
EP0000220A1 EP0000220A1 (fr) 1979-01-10
EP0000220B1 true EP0000220B1 (fr) 1981-04-29

Family

ID=6011783

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78200041A Expired EP0000220B1 (fr) 1977-06-18 1978-06-14 Dihydrouraciles, procédé pour leur préparation et médicaments les contenant

Country Status (14)

Country Link
US (1) US4216216A (fr)
EP (1) EP0000220B1 (fr)
JP (1) JPS549287A (fr)
AT (1) AT358597B (fr)
AU (1) AU3678878A (fr)
CA (1) CA1085396A (fr)
DE (2) DE2727469A1 (fr)
DK (1) DK272778A (fr)
ES (1) ES470727A1 (fr)
IE (1) IE47103B1 (fr)
IL (1) IL54916A0 (fr)
IT (1) IT1099556B (fr)
NO (1) NO782108L (fr)
ZA (1) ZA783465B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5753481A (en) * 1980-09-17 1982-03-30 Yoshitomi Pharmaceut Ind Ltd 4-hydrouracil-piperidines
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
US4579947A (en) * 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
AR242678A1 (es) * 1986-03-05 1993-04-30 Gonzalez Jorge Alberto Mejoras en instrumentos musicales de cuerda de arco.
PH25227A (en) * 1986-03-05 1991-03-27 Merrell Dow France Et Co Aromatic w-alkylamino-tetrahydro-6h-1,3-thiazin-6-one derivatives, pharmaceutical composition containing same and method of use thereof
NZ233398A (en) * 1989-04-22 1991-12-23 American Home Prod Aryl- or heteroaryl-substituted piperazine derivatives and pharmaceutical compositions
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
ATE201016T1 (de) * 1995-06-09 2001-05-15 Hoffmann La Roche Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
AU1979799A (en) * 1998-07-21 2000-02-14 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
HUP0102980A3 (en) * 1998-07-21 2003-02-28 Ranbaxy Lab Ltd Arylpiperazine derivatives useful as uroselective alpha1-adrenoceptor blockers, pharmaceutical compositions containing them and their use
KR100578987B1 (ko) 2000-09-27 2006-05-12 히다치 가세고교 가부시끼가이샤 레지스트 패턴, 그 제조방법 및 그 이용
US7611818B2 (en) 2003-11-19 2009-11-03 Hitachi Chemical Company, Ltd. Photosensitive resin composition, photosensitive element, resist pattern forming method and process for manufacturing printed circuit board
IT1392408B1 (it) 2008-12-23 2012-03-02 Texnology S R L Dispositivo di trattamento di un velo di carda

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2672460A (en) * 1952-06-24 1954-03-16 American Cyanamid Co Disubstituted piperazines and methods of preparing the same
US3406023A (en) * 1966-10-31 1968-10-15 Du Pont Herbicidal method
US3726979A (en) * 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
BE788280A (fr) * 1971-09-04 1973-02-28 Pfizer Nouvelles 1-(3-trifluoro-methyl-phenyl)-4-((amido cyclique)- alkyl) piperazines et composition pharmaceutique les contenant
US4100282A (en) * 1972-12-23 1978-07-11 Boehringer Ingelheim Gmbh N-Aryl-N'-(phenyl- or phenoxy-alkyl)-piperazines and salts thereof

Also Published As

Publication number Publication date
DE2727469A1 (de) 1978-12-21
CA1085396A (fr) 1980-09-09
IT7824660A0 (it) 1978-06-16
DK272778A (da) 1978-12-19
ATA441278A (de) 1980-02-15
JPS549287A (en) 1979-01-24
DE2860637D1 (en) 1981-08-06
IE781066L (en) 1978-12-18
IT1099556B (it) 1985-09-18
IL54916A0 (en) 1978-08-31
AU3678878A (en) 1979-12-06
JPS566420B2 (fr) 1981-02-10
US4216216A (en) 1980-08-05
IE47103B1 (en) 1983-12-28
NO782108L (no) 1978-12-19
EP0000220A1 (fr) 1979-01-10
ES470727A1 (es) 1979-01-16
ZA783465B (en) 1979-07-25
AT358597B (de) 1980-09-25

Similar Documents

Publication Publication Date Title
EP0000220B1 (fr) Dihydrouraciles, procédé pour leur préparation et médicaments les contenant
DE1695556C3 (de) 3-Alkyl-1,2,3,4,4a,9-hexahydropyrazino[1,2-f]morphanthridinderivate
CH405314A (de) Verfahren zur Herstellung von Indolylverbindungen
EP0047923B1 (fr) Dérivés de l'isoquinoléine, leurs procédés de préparation et compositions pharmaceutiques les contenant
EP0072932A2 (fr) Pipérazinones, leur préparation et leur utilisation
DE2924681A1 (de) Phenylpiperazinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2238504B2 (de) l-Phenoxy-3-alkylaminopropan-2-ol -Derivate
EP0005828A1 (fr) Nouvelles dérivés de la phénylpipérazine substitués, médicaments les contenant et procédés pour leur préparation
DE2651083C2 (fr)
DE2854308A1 (de) Anticholinergische substanzen mit antisekretorischer wirkung, ihre herstellung und verwendung
DE2434951A1 (de) 3-substituierte diphenylhydantoine
DE2461802A1 (de) Pyrazinderivate
DE2426149B2 (de) 7-Fluor-substituierte Phenothiazine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
EP0018360B1 (fr) N-(5-méthoxybenzofuran-2-ylcarbonyl)-N'-benzylpipérazine et procédé pour sa préparation
EP0431371A1 (fr) 3-Aminopyrroles, procédé pour leur préparation et leur utilisation comme médicaments
EP0064685A1 (fr) Dibenzo(de,g)quinolines, leurs procédés de préparation et les médicaments les contenant
DD219642A5 (de) Verfahren zur herstellung von bis-(piperazinyl- bzw. homopiperazinyl)alkanen
DE3223877C2 (fr)
EP0007525A1 (fr) Dérivés de la 2-(4-aminopipéridino)-3.4-dihydroquinoléine, procédés pour leur préparation, compositions pharmaceutiques les contenant et leur utilisation
DE2509797C2 (de) Phthalimidine, deren physiologisch verträgliche Säureadditionssalze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69310186T2 (de) 1,2-dihydro-2-oxo-3-aminochinoxalin derivate, ihre verwendung als heilmittel
EP0008014A1 (fr) Dérivés de la 1-(4-aminopipéridino)-3.4-dihydroisoquinoléine, procédés pour leur préparation, compositions pharmaceutiques les contenant et leur utilisation
DD216013A5 (de) Verfahren zur herstellung neuer ethendiamin- und guanidin-derivate
DE3220185A1 (de) 4-amino-benzylamin-derivate, verfahren zu ihrer herstellung, sowie ihre verwendung als pharmazeutica
DE69612413T2 (de) 1-(Hetero)Arylvinyl-5H-2,3-benzodiazepinderivative verwendbar zur Behandlung von Erkrankungen des Zentralnervensystems, sowie Benzopyrylium Intermediate zu ihrer Herstellung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19810630

REF Corresponds to:

Ref document number: 2860637

Country of ref document: DE

Date of ref document: 19810806

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19830525

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19840514

Year of fee payment: 7

Ref country code: CH

Payment date: 19840514

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19840515

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19840630

Year of fee payment: 7

Ref country code: BE

Payment date: 19840630

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19840713

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19850615

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19850630

Ref country code: BE

Effective date: 19850630

BERE Be: lapsed

Owner name: HOECHST A.G.

Effective date: 19850614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19860101

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19860228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19860301

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

EUG Se: european patent has lapsed

Ref document number: 78200041.8

Effective date: 19860728

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT